Patient Access AI Vendor Evaluation Guide

Patient Access AI Vendor Evaluation Guide

A defensible patient access AI vendor evaluation compares finalists under the same scope, evidence request, scenario set, acceptance rules, and commercial assumptions. A polished demo, a familiar logo, or a single compliance document cannot establish local workflow fit. The buyer must be able to reconstruct what was evaluated, in which configuration, who observed the result, what remains unknown, and when the decision expires.

This guide is for healthcare technology evaluation and procurement planning. It is not medical, clinical, legal, billing, coding, reimbursement, or compliance advice. Qualified local owners must determine which laws, contracts, standards, clinical controls, and accessibility duties apply to the organization, product function, data flow, population, and jurisdiction. The method below does not name or rank vendors, claim that any product passed, or supply invented pricing, performance, implementation, or ROI benchmarks.

Start with a shortlist, then evaluate finalists

Use the patient access tool shortlist guide to define the patient-access lane, apply eligibility gates, and complete candidate narrowing. That work answers whether a candidate belongs in the evaluation at all. This guide begins after that handoff, when a smaller set of finalists must answer a common RFP, run common scenarios, support buyer-observed acceptance, and expose contract, support, and exit terms.

Keep the two records separate. A shortlist can record that a candidate appears capable of self-scheduling, digital intake, referral routing, eligibility support, record access, portal assistance, or patient communication. Finalist evaluation must prove how the proposed product, module, version, tenant, interfaces, roles, and operating model behave in the buyer's bounded deployment.

The patient access workflow guide can help identify local handoffs. The broader patient access buyer guide can frame the purchasing process. Neither substitutes for the controlled comparison described here.

How to run one comparable evaluation

Create one buyer-owned evaluation workspace before vendor sessions begin. Give each finalist the same requirements, test data rules, scenario sequence, response deadline, clarification process, and evidence definitions. Preserve vendor assertions as assertions; do not silently convert a slide, portal badge, certification reference, or contract promise into a verified fact.

Each gate receives one of four statuses: pass, conditional, stop, or unknown. A pass requires evidence that is relevant to the exact deployment. A conditional status needs a named owner, bounded condition, due date, retest or review action, and expiration. A stop prevents advancement. Unknown means unknown — local owner/evidence required; it is not a neutral score or implied approval.

Use weighted scoring only after hard-stop gates are resolved. Identity and data integrity, privacy and security, accessibility and language access, clinical safety, auditability, recovery, and exit failures cannot be offset by price, presentation quality, projected savings, or a high average score. The general healthcare AI vendor checklist can supplement the patient-access-specific gates below.

Freeze the comparison window as well as the protocol. If one finalist supplies a revised build, new contract, or corrected evidence, record the change and give the other finalists the same opportunity where fairness requires it.

At the end of each gate, preserve dissent and unresolved limitations. A concise decision record is more useful than a large evidence folder whose contents cannot be connected to requirements, owners, observations, and expiration dates.

Gate 1: bind the candidate and deployment identity

Name the exact candidate being evaluated: legal entity, product, module, build or release, hosting model, tenant, environment, enabled features, model or rules version when relevant, and proposed subcontractors. Then bind it to a workflow, population, site, specialty, channel, language set, source system, authoritative record, downstream action, and human decision authority.

Do not accept a case study from another module or an enterprise-wide claim when the proposed deployment is narrow. A vendor may have multiple offerings with different data flows, certifications, support teams, and contract terms. Record which claims apply to which component and which remain out of scope.

Evidence request: a signed scope response, architecture and deployment inventory, feature/configuration list, exclusions, responsible vendor contacts, and a versioned statement tying every cited artifact to the proposed deployment.

Stop the gate when the vendor cannot identify the evaluated product or when material functions, entities, data flows, or human authorities remain undisclosed. Unknown rule: a missing local workflow owner or an unbound vendor claim remains unknown rather than passing by analogy.

Gate 2: run the common demo and scenario protocol

Require finalists to run the same buyer-authored scenarios rather than a vendor-selected happy path. Cover ordinary work and negative, boundary, outage, recovery, and handoff cases. Capture expected behavior before the session, observed behavior during it, downstream records afterward, deviations, defects, and retest results.

For scheduling, the HL7 FHIR R4 Appointment resource describes states and participant responses, while the Schedule resource explains availability semantics. Those specifications help form precise test cases, but an available slot does not guarantee that local booking rules, authorization, identity, referral, or resource constraints permit an appointment.

Evidence request: a completed common script showing test-data provenance, environment, product version, operator, timestamps, expected and observed results, affected records, screenshots or logs where permitted, defects, corrective action, and buyer-observed retest.

Stop the gate when a finalist refuses comparable scenarios, substitutes a recording for required observation, or cannot show how a failed or partial action is detected and reconciled. Unknown rule: any scenario not observed in the proposed configuration stays unknown even if the vendor says another customer completed it.

Gate 3: trace data, legal roles, privacy, and security

Map every data element from collection through use, disclosure, storage, model or rules processing, support access, retention, deletion, export, and backup. Distinguish the covered entity, business associate, subcontractor, consumer-app, and other roles rather than applying one label to an entire corporate group.

The HIPAA right-of-access regulation supports questions about designated record sets and individual access.

HHS business associate guidance describes example relationships and contractual duties. An HHS FAQ on business-associate obligations addresses records held by a business associate. These sources do not make every patient-facing app a business associate or prove that a proposed agreement fits the actual flow.

Use the current HHS Security Rule summary to frame administrative, physical, and technical control questions.

The technical safeguards in 45 CFR 164.312 provide a more specific regulatory reference.

HHS cloud-computing guidance addresses cloud-service relationships and risk analysis. A BAA or encryption claim is not proof that access, audit, integrity, authentication, transmission, incident, backup, and recovery controls work in the configured deployment.

For a product or entity outside HIPAA, do not assume that no privacy or breach duties exist. The FTC Health Breach Notification Rule and mobile health app best practices provide separate questions about health-record vendors, permissions, minimization, authentication, third-party components, notices, claims, and security lifecycle. Local counsel must determine applicability.

Evidence request: a versioned data-flow map, role and agreement matrix, subprocessor list, permitted-use and secondary-use terms, retention/deletion schedule, access-control and audit evidence, incident duties, backup/restore results, and exit return or deletion obligations.

Stop the gate when undisclosed secondary use, irreconcilable contract language, prohibited access, missing auditability, or untestable return/deletion terms create an unresolved hard stop. Unknown rule: “BAA available,” “HIPAA ready,” or “encrypted” without configuration-specific evidence remains unknown.

Gate 4: prove integration, identity, and reconciliation

Inventory every interface and bind it to the exact standard, implementation guide, version, endpoint, environment, authentication flow, read/write authority, data scope, mapping, and system of record. Test patient matching, duplicate and overlay prevention, stale data, partial success, retry, idempotency, queue behavior, rollback, replay, and affected-record reconciliation.

If certification is in scope, capture the exact module, criterion, version, and public record. The ONC HTI-1 Final Rule page provides the rule context.

The ISP entry for §170.315(g)(10) standardized APIs identifies a bounded criterion and referenced standards. Neither proves local interoperability, complete workflow behavior, write authority, data quality, or successful reconciliation.

For information-access questions, begin with the information blocking regulation.

ASTP/ONC information blocking resources provide additional official explanations. Determine the actor, electronic health information, practice, facts, and exception conditions locally. Do not treat every security review, identity check, workflow delay, or API limitation as automatically permitted or prohibited.

Patient safety and identity controls should also draw questions from the current SAFER Guides. These are recommended practices and self-assessment resources, not a product certification or proof that a vendor configuration is safe.

Evidence request: an interface register, identity and mapping specification, authorization matrix, certification/applicability record where relevant, common integration tests, message and API logs, error/retry evidence, target-record inspection, rollback results, and reconciliation signoff by the buyer's data owner.

Stop the gate for unresolved wrong-patient risk, unauthorized write paths, undetectable partial failure, missing audit trail, or inability to enumerate and correct affected records. Unknown rule: FHIR support, ONC certification, or an HTTP success without end-to-end buyer observation remains unknown.

Gate 5: test accessibility, language, and patient experience

Evaluate complete representative tasks, not isolated screens. Include account creation and authentication, search and selection, form entry and errors, schedule/reschedule/cancel, document upload or download, messaging, timeouts, recovery, and escalation. Test relevant devices, browsers, zoom, keyboard, screen reader, speech input, mobile orientation, and communication alternatives with qualified evaluators and representative users where appropriate.

For HHS funding recipients, the HHS Section 504 detailed fact sheet describes the recipient scope, WCAG 2.1 AA requirement, exceptions, and effective-communication duties. HHS later extended the web and mobile accessibility compliance dates to 2027 or 2028 depending on recipient size. Those dates and duties must not be generalized to every vendor or every buyer.

Use the W3C WCAG-EM methodology to structure scope, representative sampling, evaluation, and reporting. The W3C summary of what is new in WCAG 2.2 can inform a separate forward-looking review, but publication of a technical recommendation does not by itself establish legal adoption for a buyer. A VPAT, ACR, or automated scan does not prove accessibility of the configured end-to-end task.

For language access, review the HHS Section 1557 language-access letter with counsel. The source discusses meaningful access and also flags litigation-related stays or injunctions affecting some provisions. The buyer must verify current federal, state, contractual, and program duties rather than treating a language list or machine translation as compliance.

Evidence request: a task/sample matrix, test method, assistive technology and device record, language and content version, barriers, workarounds, qualified human assistance, interpreter handoff, complaint and correction path, owner, remediation date, and buyer-observed retest.

Stop the gate when an essential task is inaccessible, a required language or assistance path fails, or the vendor cannot provide a safe human alternative. Unknown rule: an untested task, population, device, language, or configuration remains unknown and cannot inherit a blanket accessible label.

Gate 6: validate implementation, support, and continuity

Compare the proposed staffing, buyer dependencies, test environments, training, migration, cutover, monitoring, support coverage, escalation, and change-notice process. Ask the vendor to identify which work is included, which depends on third parties, and what happens when an assumed interface, data feed, or customer resource is unavailable.

Run operational scenarios for vendor-service outage, source-system outage, degraded interface, expired credential, duplicate submission, delayed response, inaccessible message, staffing shortfall, and restore from backup. Confirm the manual process, backlog protection, notification, recovery order, replay controls, and post-recovery reconciliation. A generic disaster-recovery document is not the same as a buyer-observed recovery result.

Require support terms to distinguish severity definitions, coverage windows, response, restoration target, resolution process, status communication, escalation authority, problem review, and remedy. Do not rewrite a response target as a guaranteed resolution time. Do not assume that an implementation reference from another module, population, or integration predicts local effort.

Evidence request: a dependency and responsibility matrix, environment plan, training and competency record, cutover and rollback plan, support model, continuity runbook, change-notice process, observed outage/recovery test, open-defect register, and transition owner.

Stop the gate when the organization cannot maintain a safe manual path, preserve queued work, recover records, or obtain support for a high-impact failure. Unknown rule: implementation time, staffing, uptime, recovery, and support performance remain unknown until tied to dated terms and local evidence.

Gate 7: compare commercial, contract, and exit terms

Normalize the commercial response before comparing price. Record the legal entity, product and module, environment, locations, users, transactions or volume unit, included services, implementation assumptions, minimums, overages, third-party costs, travel, taxes, term, renewal, price change, and quote expiration. A low headline price is not comparable when scope and assumptions differ.

Read the order form, master agreement, data-processing terms, BAA when applicable, service levels, acceptable-use terms, support policy, subprocessor terms, and security exhibits together. Record order of precedence and conflicts. Link every promised feature, control, support level, acceptance criterion, and remedy to enforceable language or label it as a nonbinding vendor assertion.

Design exit before selection. Require export of buyer data, configuration, rules, templates, audit history, consent or preference records, open appointments or requests, message state, and unresolved queues in usable formats. Specify transition assistance, access period, knowledge transfer, deletion timing, backup treatment, verification evidence, fees, and responsibilities when the vendor or buyer terminates.

The PHI evaluation guide and HIPAA-oriented tools guide can add questions, but neither turns contractual language into a blanket compliance finding.

Evidence request: a normalized pricing and assumption sheet, contract deviation log, SLA/remedy matrix, acceptance terms, renewal/change controls, subprocessor notice terms, complete exit plan, sample export, transition duties, deletion evidence, and accountable owner for every open issue.

Stop the gate when a critical promise is nonbinding, cost cannot be normalized, the vendor can materially change processing without acceptable control, or the buyer cannot retrieve and transition essential records. Unknown rule: unquoted work, unresolved contract conflict, untested export, or undefined deletion remains unknown rather than “standard.”

Gate 8: accept and renew from buyer-observed evidence

Define acceptance before contract signature or pilot execution. Each criterion needs a scoped cohort, environment, source, numerator and denominator where a metric is used, exclusions, observation method, owner, threshold, failure action, defect rule, and retest requirement. Vendor dashboard values are inputs; the buyer should be able to reproduce the cohort and inspect source records.

Separate technical acceptance, operational readiness, privacy/security approval, accessibility/language approval, clinical-safety review when relevant, commercial acceptance, and executive risk acceptance. A conditional decision must state the permitted workflow, population, duration, safeguards, unresolved evidence, stop authority, due date, and approval expiration.

If a function influences urgency, triage, diagnosis, treatment, or care routing, evaluate the exact function and intended use through FDA's Digital Health Policy Navigator and Clinical Decision Support Software guidance. These resources support a structured review; they do not issue a binding product determination through this article. “AI,” “administrative,” or “human in the loop” is not enough to decide the regulatory branch.

Set renewal and reapproval triggers: material feature or model change, new data use, subprocessor change, interface/version change, new population or language, security incident, accessibility regression, support deterioration, ownership change, legal or standards change, repeated exception, and evidence expiration. The healthcare AI pilot guide can help structure a bounded implementation, while the ROI and implementation guide can hold local financial assumptions after safety and evidence gates are resolved.

Evidence request: a signed acceptance packet containing gate status, source records, buyer-observed results, defects and retests, unresolved risks, conditional scope, financial assumptions, decision owners, stop authority, evidence expiry, monitoring plan, and renewal or change-triggered review dates.

Stop the gate when acceptance depends only on vendor testimony, when the buyer cannot reproduce a critical result, or when a hard-stop issue remains unresolved. Unknown rule: a missing baseline, denominator, source record, reviewer, or expiry makes the affected criterion unknown. Projected value cannot turn it into a pass.

Procurement questions by accountable owner

Give each question one accountable buyer owner and a destination artifact. A committee can contribute evidence, but shared ownership must not mean that nobody decides.

Patient-access operations

• Which schedule, referral, eligibility, intake, message, or queue state is authoritative, and who can correct or pause it?
• What should happen for incomplete data, duplicate requests, no availability, failed eligibility, patient disagreement, and abandoned sessions?
• Which manual process protects patients and queued work during downtime, and how is the backlog reconciled after recovery?

Registration, HIM, and identity

• Which identity fields and match thresholds are used, and who resolves duplicates, overlays, merges, and uncertain matches?
• How are record access, amendment, accounting, proxy, and designated-record-set requests routed when vendor-held data is involved?
• Can the buyer enumerate every affected patient and downstream record after an error, rollback, replay, merge, or correction?

Privacy, legal, and compliance

• Which entity performs each collection, use, disclosure, support, storage, and deletion activity, under which role and agreement?
• Which secondary uses, model-improvement uses, subprocessors, retention periods, and cross-border or cross-entity transfers are permitted?
• Who verifies the current applicability of HIPAA, CMS, ONC, Section 504, Section 1557, FTC, FDA, state, contractual, and program requirements?

Security

• How does the configured deployment enforce least privilege, authentication, authorization, audit, integrity, and transmission protection?
• What vulnerability, patch, secrets, dependency, incident-notification, forensics, and customer-coordination evidence can the buyer inspect?
• When were backup and restore last tested for the proposed service, and how will the buyer verify completeness and affected records?

IT and interoperability

• Which exact interface, standard, implementation guide, profile, version, endpoint, and environment is proposed for each data flow?
• Which system can read or write each field, and how are mapping, idempotency, stale data, partial failure, retry, rollback, and replay controlled?
• What evidence proves target-record reconciliation, production variance management, version upgrades, change notice, and safe rollback?

Accessibility, language, and patient experience

• Which complete tasks, devices, browsers, assistive technologies, user needs, and representative samples were evaluated?
• Which languages and vital content are supported, where does qualified human or interpreter assistance enter, and what are machine-translation limits?
• How can a patient report a barrier, escape an automation loop, correct an error, request an alternative, and learn whether the issue was resolved?

Clinical safety and quality

• Which functions can affect urgency, triage, clinical routing, care advice, or delayed access, and what is each intended use?
• What failure modes could cause harm, who reviews them, what is the stop threshold, and how are affected cases found and corrected?
• Which feature, model, workflow, population, or evidence changes require new clinical, quality, regulatory, or safety review?

Procurement, finance, implementation, and vendor management

• Which volume, staffing, integration, environment, training, travel, third-party, overage, renewal, and price-change assumptions make quotes comparable?
• Which acceptance, SLA, remedy, support, change, subprocessor, transition, export, and deletion commitments are enforceable?
• Who owns each dependency, conditional item, evidence expiry, renewal review, exit test, and unresolved vendor or buyer action?

Buyer-owned finalist artifacts

These artifacts belong to the buyer and should remain exportable outside the vendor portal. Their purpose is traceability, not paperwork volume. A portal badge, slide, certification, VPAT/ACR, security packet, or contract promise does not replace a buyer-observed result.

RFP Evidence Matrix

Create one row per requirement with the accountable owner, hard-stop flag, vendor assertion, authority record, buyer-observed result, product/module/version, environment, evidence date, limitation, status, expiry, and next action. Use pass, conditional, stop, or unknown without default numeric weighting. This matrix is not a vendor ranking; it is the index to the evidence behind a bounded decision.

Common Scenario and Demo Protocol

Preserve the same test data rules, normal cases, negative cases, boundary cases, outage and recovery cases, expected outcomes, observed outcomes, downstream records, defect IDs, and retest decisions for every finalist. Record vendor assistance so an operator difference is not mistaken for a product difference.

Data, Integration, and Applicability Dossier

Combine the data-flow map, entity and agreement roles, subprocessors, interfaces and versions, identity rules, field mappings, read/write authority, access and certification branches, legal applicability questions, and unresolved unknowns. Date each source and distinguish current rule, proposed change, technical standard, certification scope, contractual term, and local test.

Accessibility and Language Validation Record

For each representative task, record the sample, assistive technology, device, browser, language, content version, evaluator method, result, barrier, workaround, human handoff, complaint path, owner, remediation, and retest date. Do not collapse scan findings and end-to-end human evaluation into one unsupported pass.

Implementation, Support, Contract, and Exit Register

Track responsibilities, dependencies, environments, staffing, training, cutover, rollback, monitoring, severity and response terms, remedies, change and subprocessor notices, continuity evidence, export fields and formats, open-queue transfer, transition assistance, deletion, fees, owners, and due dates. Link promises to governing contract language.

Decision, Acceptance, and Renewal Packet

Summarize gate statuses, acceptance evidence, defects and retests, unresolved risks, conditional scope, commercial assumptions, approval owners, stop authority, monitoring, evidence expiry, renewal triggers, and change-triggered reapproval. Preserve negative findings and superseded decisions so a later reviewer can reconstruct why the boundary exists.

Common scenario packet

Use synthetic or appropriately controlled test data approved by the buyer. Do not place live PHI into a demo environment merely to make a scenario realistic. Adjust the packet to the actual product lane and proposed permissions.

• Request, confirm, reschedule, cancel, waitlist, and no-show handling with the source and target status inspected.
• Wrong, duplicate, incomplete, stale, mismatched, inaccessible, or unsupported input with correction and affected-record enumeration.
• Referral, eligibility, authorization, or scheduling rule that requires a human decision, plus a patient disagreement or requested alternative.
• Authentication failure, proxy or caregiver access, timeout, interrupted session, channel switch, and recovery without lost or duplicated work.
• Screen-reader, keyboard, zoom, mobile orientation, error identification, language assistance, document upload/download, and message delivery.
• Source-system, interface, vendor-service, and downstream outage with queue protection, notification, manual operation, replay, rollback, and reconciliation.
• Suspicious access, incident escalation, audit retrieval, support handoff, vendor change notice, export, termination, and verified deletion.

Each scenario should identify the expected result before the session. Capture the observed result, source record, downstream effect, exception, operator, configuration, date, defect, retest, and status afterward. If the buyer cannot observe a relevant control safely during evaluation, state the alternate evidence and limitation instead of marking it complete.

FAQs

Should the highest weighted score win?

No. Weighted scoring can compare preference items after mandatory gates are resolved, but it can conceal a critical failure. Identity and integrity, privacy and security, accessibility and language, clinical safety, auditability, recovery, and exit hard stops cannot be offset by price, presentation, feature count, or projected value. Missing evidence stays unknown — local owner/evidence required.

Does a BAA make the deployment HIPAA compliant?

No. A BAA may be required for a particular relationship and must address specified duties, but its existence does not prove that the parties classified roles correctly or that the configured safeguards, permitted uses, subprocessors, retention, incident response, access support, return, and deletion work as required. Local privacy, security, legal, and compliance owners must assess the actual deployment.

Does FHIR support or ONC certification prove local integration?

No. A standard or bounded certification can establish useful capabilities within its stated scope, but it does not prove local interoperability, identity accuracy, authorization, mapping, write behavior, downstream completion, exception handling, recovery, or reconciliation. Bind the claim to exact versions and inspect buyer-observed source and target records.

Does a VPAT, ACR, or automated scan prove accessibility?

No. Each can contribute evidence, but it does not prove accessibility of the configured product, complete task, mobile experience, support content, authentication flow, document, or third-party component. Use representative-sample evaluation, relevant assistive technology, human review, barrier tracking, and retest. An untested task remains unknown.

Is every patient-access product a CMS Patient Access API?

No. The CMS Interoperability and Prior Authorization final rule fact sheet identifies specific impacted payers, APIs, provisions, and 2026 or 2027 compliance-date branches. CMS also publishes API standards and implementation-guide resources. Ordinary provider scheduling, intake, portal, or messaging software should not inherit that label solely because it supports patient access.

Can a vendor demo count as buyer acceptance evidence?

A demo can create evidence only for the exact scenario, configuration, environment, operator, data, and observation recorded. It cannot prove unshown cases, production performance, contractual commitment, or sustained control operation. Final acceptance should reference reproducible buyer-observed results, unresolved limitations, defects and retests, decision owners, expiration, and change triggers.

Evidence boundary

The sources linked above define rules, technical standards, regulatory guidance, accessibility methods, and voluntary risk frameworks. The NIST AI Risk Management Framework and NIST Cybersecurity Framework can organize governance and risk questions, but each is a framework rather than a vendor approval, legal determination, compliance certificate, or local performance result.

No named vendor was evaluated for this guide. No product test, customer interview, price, implementation duration, performance rate, accessibility result, clinical result, cost saving, or ROI is claimed. Every local deployment decision still requires product- and configuration-specific evidence, accountable review, and current source verification.